Emerging Cancer Vaccines: Market Forecasts, New Developments and Pipeline Analysis

3rd Edition

Publication Date	November 2008
Publisher	Kalorama Information
Product Type	Report
Pages	250
ISBN Number	not applicable
Product Code	KAL00140

Buy this product or for assistance call +44 20 7060 7474

PDF £2,400.00$3992 | €2686

FAX Order above formats by FAX

Summary

It is the general consensus of scientists that cancer vaccines will become a reality. Overall the cancer treatment market continues to grow and this demand sets the stage for vaccine products.Several promising vaccines: the propholactic Gardasil has created a pathway for new vaccine products. MVax, OconVax in late stage development and are preparing for regulatory review in the United States, Europe, Canada, or other international regions. Many of the products with potential approval status over the coming years are already in Phase III development, have orphan drug status, SPA status, or Fast Track status. This provides a promising future for many of these products. Additionally, some products in international regions have been granted compassionate use status which is significant in evaluating need on a patientbypatient basis.

In this report, Kalorama Information provides a realistic estimate of the cancer vaccine for the near term for the following products:

Melonoma Vaccines
Lung Cancer Vaccines
Prostate Cancer Vaccines
Cervical Cancer Vaccines
Brain Cancer Vaccines
Colon/Rectal Cancer Vaccines
Breast Cancer Vaccines
Lymphoma Vaccines
Ovarian Cancer Vaccines
Leukemia Vaccines
Bladder Cancer Vaccines

As part of its exhaustive research and analysis, this report provides:

Forecasts for Future Revenues from Cancer Vaccines
Cancer Epidemiology
Reviews of Products in the Pipeline
Detailed Profiles of 13 Companies Operating in the Cancer Vaccine Market
Directory of Related Companies

Some of the issues discussed in this report important for anyone operating in this market include:

Introduction
Early Detection and Screening
Monoclonal Antibodies and Therapeutic Vaccines
Political and Social Pressure
Insurance and Reimbursement Issues
Personalized Medicine
Pharmacogenomics
Vaccine Strategies
New Genetic Technique
Future Growth in Vaccines

As part of its detailed coverage of developments in cancer vaccines..the following companies are profiled in this report:

Antigenics, Inc.
Avax Technologies, Inc.
Biovest International, Inc.
Cell Genesys, Inc.
Dendreon Corporation
Genitope Corporation
GlaxoSmithKline plc
Merck & Company, Inc.
Northwest Biotherapeutics, Inc.
NovaRx
Oncothyreon
Vaccinogen
Vical, Inc.

Content

Chapter One: Executive Summary
- Introduction
- Scope and Methodology
- Size and Growth of the Market
- Issues and Trends Affecting Market
- Leading Competitors
Chapter Two: Introduction
- Introduction
- History and Growth of the Cancer Treatment Market
- Types of Vaccines
- Antigen/Adjuvant Vaccines
- Whole Cell Tumor Vaccines
- Dendritic Cell (DC) Vaccines
- Viral Vectors and DNA Vaccines
- Idiotype Vaccines
- Types of Therapeutic Vaccines
- PatientSpecific Vaccines
- Prostate Specific Antigen
- Sialyl Tn
- Heat Shock Proteins
- Ganglioside Molecules
- Carcinoembryonic Antigen (CEA)
- MART1
- Tyrosinase
- Adjuvants
- Industry Structure
- Demographics and Statistics
- Growing and Aging Population
- Life Expectancy and Cancer
Chapter Three: Cervical Cancer Vaccines
- Overview
- Description of Vaccines on the Market
- Gardasil/Silgard
- Cervarix
- Description of Vaccines in Development
- TG 4001/R3484
- HspE7
- Lovaxin C
- VGX3100
- CA9
- Market Summary
- Current and Potential Competitors and Analysis, 2012
Chapter Four: Colon/Rectal Cancer Vaccines
- Overview
- Description of Vaccines on the Market
- OncoVAX
- Description of Vaccines in Development
- OncoVAX
- TroVAX
- Avicine
- CEA VRP Vaccine
- Collidem
- IMA910
- LapuleucelT
- Oncophage
- CDX130701
- Tumor Associated Antigen Therapeutic Vaccine CEA DNA Cancer Vaccine
- MKC1106PP
- Market Summary
- Potential Competitors and Analysis, 2012
Chapter Five: Lung Cancer Vaccines
- Overview
- Description of Vaccines in Development
- Lucanix
- MAGEA3 Peptide
- Stimuvax
- EGF Cancer Vaccine
- GV1001
- HyperAcute Lung
- IDM 2101 (EP2101)
- Oncophage
- INGN 225
- TG 4010
- LungVAX
- Tumor Associated Antigen Therapeutic Vaccine CEA DNA Cancer Vaccine
- DC Vax
- L523S
- Market Summary
- Potential Competitors and Analysis, 2012
Chapter Six: Lymphoma Vaccines
- Overview
- Description of Vaccines in Development
- MyVax
- BiovaxID
- FavId
- TG 1042
- Market Summary
- Potential Competitors and Analysis, 2012
Chapter Seven: Melanoma Vaccines
- Overview
- Description of Vaccines on the Market
- Description of Vaccines in Development
- MVAX
- GMK
- Allovectin7
- MDX1379 with Combination Treatment MDX010
- Oncophage
- MAGEA3 ASCI 3
- Uvidem
- AGI101H Vaccine
- ALVAC Vaccine
- HyperAcute Melanoma
- Market Summary
- Potential Competitors and Analysis, 2012
Chapter Eight: Prostate Cancer Vaccines
- Overview
- Description of Vaccines in Development
- Provenge
- DCVaxProstate
- GVAX
- ProstAtak
- TroVAX
- Telomerase Cancer Vaccine
- MVABN Prostate
- HyperAcute Prostate
- MKC1106PP
- Market Summary
- Potential Competitors and Analysis, 2012
Chapter Nine: Breast Cancer Vaccines
- Overview
- Description of Vaccines in Development
- INGN 225
- CEA VRP Vaccine
- MVABN HER2
- LapuleucelT
- PX 104.1
- CDX130702
- Tumor Associated Antigen Therapeutic Vaccine CEA DNA Cancer Vaccine
- MKC1106PP
- Market Summary
Chapter Ten: Gastrointestinal Cancer Vaccines
- Overview
- Description of Vaccines in Development
- GV 1001
- GI4000
- Avicine
- GVAX
- HyperAcute Pancreas
- Oncophage
- CDX130701
- CRS100
- CRS207
- DC Vax
- MKC1106PP
- Market Summary
Chapter Eleven: Renal Cancer Vaccines
- Overview
- Description of Vaccines on the Market
- Oncophage
- Description of Vaccines in Development
- Oncophage
- Reniale
- TroVAX
- IMA901
- AGS003
- MDX1106
- MKC1106PP
- Market Summary
- Potential Competitors And Analysis, 2012
Chapter Twelve: Brain Cancer Vaccines
- Overview
- Glioblastoma
- Neuroblastoma
- Description of Vaccines in Development
- DCVaxBrain
- CDX110
- GliAtak
- Oncophage
- Market Summary
Chapter Thirteen: Bladder Cancer Vaccines
- Overview
- Description of Vaccines on the Market
- BCG Therapy (OncoTICE Organon Teknika) (ImmucystSanofi Pasteur)(PacisShire Pharmaceuticals)
- Description of Vaccines in Development
- Bexidem
- CG0070
- MDX130701
- Market Summary
Chapter Fourteen: Ovarian Cancer Vaccines
- Overview
- Description of Vaccines in Development
- OVax Autologous Cell Vaccine
- LapuleucelT
- Tumor Associated Antigen Therapeutic Vaccine CEA DNA Cancer Vaccine
- MKC1106PP
- Market Summary
Chapter Fifteen: Leukemia Vaccines
- Overview
- Description of Vaccines in Development
- GVAX
- PR1 Peptide Vaccine
- AGS005
- Market Summary
Chapter Sixteen: Issues And Trends Affecting The Cancer Vaccine Market
- Introduction
- Early Detection and Screening
- Monoclonal Antibodies and Therapeutic Vaccines
- Political and Social Pressure
- Insurance and Reimbursement Issues
- Personalized Medicine
- Pharmacogenomics
- Vaccine Strategies
- New Genetic Technique
- Future Growth in Vaccines
Chapter Seventeen: The Cancer Vaccine Market: Market Forecasts
- Overview
- Total Market Size and Forecast
- Market and Competitor Analysis
Chapter Eighteen: Cancer Vaccine Corporate Profiles
- Introduction
- Antigenics, Inc
- Avax Technologies, Inc
- Biovest International, Inc
- Cell Genesys, Inc
- Dendreon Corporation
- Genitope Corporation
- GlaxoSmithKline plc
- Merck & Company, Inc
- Northwest Biotherapeutics, Inc
- NovaRx
- Oncothyreon
- Vaccinogen
- Vical, Inc
chapter nineteen: company names and addresses
table of exhibits
chapter one: executive summary
- Table 11: Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets, 20082012
- Figure 11: Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets, 20082012
Chapter Two: Introduction
- Table 21: Estimated and Projected World Cancer Incidence by Selected Types of Cancer, 2007 and 2020
- Figure 21: Estimated and Projected World Cancer Incidence by Selected Types of Cancer, 2007 and 2020
- Table 22: Total Cancer Incidence by Sex and Country, 2007 Estimates
- Figure 22: Total Cancer Incidence by Sex and Country
- Table 23: World Population by Selected Geographical Region, 20072050
- Figure 24: World Population by Selected Geographical Region, 20072050
- Table 24: Estimated World Population by Age and Geographical Region, 2007
- Figure 24: Estimated World Population by Age and Geographical Region, 2007
- Table 25: Percent Population Over 65 by Year and Region
- Figure 25: Estimated World Population by Age, 2007 and 2050
- Table 26: Life Expectancy at Birth by Selected Countries, 2006
- Table 26: United States Average Years of Life Lost Per Person Dying of Cancer, All Races, Both Sexes, 2004
- Table 27: United States Estimated PersonYears of Life Lost Due to Cancer, All Races, Both Sexes, 2004
Chapter Three: Cervical Cancer Vaccines
- Table 31: Estimated World Incidence of Cervical Cancer by Country, 2007
- Figure 31: Estimated World Incidence of Cervical Cancer by Country, 2007
- Table 32: Cervical Cancer Vaccines Approved and in the Pipeline
- Table 33: The Developing Cervical Cancer Vaccine Market, 20082012
- Figure 32: The Developing Cervical Cancer Vaccine Market, 20082012
- Table 34: The Developing Cervical Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
- Figure 33: The Developing Cervical Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
- Figure 34: Anticipated Product Sales by Year for Cervical Cancer Vaccines, 20082012
Chapter Four: Colon/Rectal Cancer Vaccines
- Table 41: Estimated World Incidence of Colon/Rectal Cancer by Country, 2007
- Figure 41: Estimated World Incidence of Colon/Rectal Cancer by Country, 2007
- Table 42: Colon/Rectal Cancer Vaccines in the Pipeline
- Table 43: The Emerging Colon/Rectal Cancer Vaccine Market, 20082012
- Figure 42: The Emerging Colon/Rectal Cancer Vaccine Market, 20082012
- Figure 43: Anticipated Product Sales by Year for Emerging Colon/Rectal Cancer Vaccines, 20082012
Chapter Five: Lung Cancer Vaccines
- Table 51: Types of Primary Lung Cancer
- Table 52: Estimated World Incidence of Lung Cancer by Country, 2007
- Figure 51: Estimated World Incidence of Lung Cancer by Country, 2007
- Table 53: Lung Cancer Vaccines in the Pipeline
Chapter Six: Lymphoma Vaccines
- Table 61: Classification of NonHodgkins Lymphomas
- Table 62: Estimated World Incidence of Lymphoma by Country, 2007
- Figure 61: Estimated World Incidence of Lymphoma by Country, 2007
- Table 63: Lymphoma Vaccines in the Pipeline
- Table 64: The Emerging Lymphoma Vaccine Market, 20082012
- Figure 62: The Emerging Lymphoma Vaccine Market, 20082012
- Table 65: The Emerging Lymphoma Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
- Figure 63: The Emerging Lymphoma Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
- Figure 64: Anticipated Product Sales by Year for Emerging Lymphoma Vaccines, 20102012
Chapter Seven: Melanoma Vaccines
- Table 71: Malignant Condidtions of the Skin
- Table 72: Estimated World Incidence of Melanoma by Country, 2007
- Figure 71: Estimated World Incidence of Melanoma by Country, 2007
- Table 73: Melanoma Vaccines in the Pipeline
- Table 74: The Developing Melanoma Vaccine Market, 20082012
- Figure 72: The Developing Melanoma Vaccine Market, 20082012
- Table 75: The Developing Melanoma Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
- Figure 73: The Developing Melanoma Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
- Figure 74:Anticipated Product Sales by Year for Developing Melanoma Vaccines, 20102012
Chapter Eight: Prostate Cancer Vaccines
- Table 81: Estimated World Incidence of Prostate Cancer by Country, 2007
- Figure 81: Estimated World Incidence of Prostate Cancer by Country, 2007
- Table 82: Prostate Cancer Vaccines in the Pipeline
- Table 83: The Emerging Prostate Cancer Vaccine Market, 20082012
- Figure 82: The Emerging Prostate Cancer Vaccine Market, 20082012
- Table 84: The Emerging Prostate Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
- Figure 83: The Emerging Prostate Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
- Figure 84: Anticipated Product Sales by Year for Emerging Prostate Vaccines, 20102012
Chapter Nine: Breast Cancer Vaccines
- Table 91: Estimated World Incidence of Breast Cancer by Country, 2007
- Figure 91: Estimated World Incidence of Breast Cancer by Country, 2007
- Table 92: Breast Cancer Vaccines in the Pipeline
Chapter Ten: Gastrointestinal Cancer Vaccines
- Table 101: Estimated World Incidence of Gastrointestinal Cancer by Country, 2007
- Figure 101: Estimated World Incidence of Gastrointestinal Cancer by Country, 2007
- Table 102: Gastrointestinal Cancer Vaccines in the Pipeline
Chapter Eleven: Renal Cancer Vaccines
- Table 111: Estimated World Incidence of Renal Cancer by Country, 2007
- Figure 111: Estimated World Incidence of Renal Cancer by Country, 2007
- Table 112: Renal Cancer Vaccines in the Pipeline
- Table 113: The Developing Renal Cancer Vaccine Market, 20082012
- Figure 112: The Developing Renal Cancer Vaccine Market, 20082012
- Table 114: The Developing Renal Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
- Figure 113: The Developing Renal Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
- Figure 114: Anticipated Product Sales by Year for Renal Cancer Vaccines, 20082012
Chapter Twelve: Brain Cancer Vaccines
- Table 121: Estimated World Incidence of Brain Cancer by Country, 2007
- Figure 121: Estimated World Incidence of Brain Cancer by Country, 2007
- Table 122: Brain Cancer Vaccines in the Pipeline
Chapter Thirteen: Bladder Cancer Vaccines
- Table 131: Estimated World Incidence of Bladder Cancer by Country, 2007
- Figure 131: Estimated World Incidence of Bladder Cancer by Country, 2007
- Table 132: Bladder Cancer Vaccines in the Pipeline
Chapter Fourteen: Ovarian Cancer Vaccines
- Table 141: Estimated World Incidence of Ovarian Cancer by Country, 2007
- Figure 141: Estimated World Incidence of Ovarian Cancer by Country, 2007
- Table 142: Ovarian Cancer Vaccines in the Pipeline
Chapter Fifeteen: Leukemia Vaccines
- Table 151: TYPES OF LEUKEMIA
- Table 152: Estimated World Incidence of Leukemia by Country, 2007
- Figure 151: Estimated World Incidence of Leukemia Cancer by Country, 2007
- Table 153: Leukemia Vaccines in the Pipeline
Chapter Sixteen: Issues And Trends Affecting The Cancer Vaccine Market
- Table 161: Cancer Detection Tests
Chapter Seventeen: The Cancer Vaccine Market: Market Forecasts
- Table 171: Cancer Vaccines: Developing and Emerging Cancer VaccineMarkets, 20082012
- Figure 171: Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets, 20082012
- Figure 172: Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets by Percent and Vaccine Indication, 2012
Cancer Vaccine Corporate Profiles
Company Names And Addresses